* Repeated plasma exchange removes sufficient HIT-IgG to achieve negative serotonin-release assay (SRA) despite ongoing strong-positive EIA * Serially-diluted HIT sera tested in both SRA and EIA show that SRA negativity can be achieved with minimal decrease in EIA reactivity
Introduction
Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction caused by plateletactivating IgG antibodies that recognize multimolecular PF4/heparin complexes. 1 Therapeutic plasma exchange (TPE) has been recommended as a way to remove HIT antibodies quickly, as might be required to permit administration of heparin for urgent cardiac surgery. 2 However, HIT antibodies (IgG) are not as effectively removed by TPE as IgM. 3 Using serial pre-/post-TPE sera obtained from a patient with subacute HIT (i.e., recent HIT with platelet count recovery but persisting HIT antibodies 4 ) who underwent repeated TPE pre-cardiac surgery, we compared antibody reactivity by the 14 C-serotonin-release assay (SRA) 5 -a functional (platelet activation) test for HIT antibodies-versus an IgG-specific anti-PF4/heparin enzyme-immunoassay (EIA). 6 We found that while a negative SRA could be achieved quickly post-TPE, corresponding EIA reactivities remained strongly positive. This observation proved to be a general feature of HIT antibody reactivity, as 15 other acute HIT sera showed rapid diminution of SRA reactivity upon serial dilutions, but with major reductions in EIA reactivity requiring much greater sample dilutions.
Case Report
A 76-year-old female with renal carcinoma invading the inferior vena cava (IVC)/right atrium developed HIT without thrombosis (4Ts score, 7 6 points), with strong-positive SRA and EIA, and with uneventful platelet count recovery during fondaparinux 7.5mg once-daily subcutaneously. Cardiac surgery was scheduled three months post-HIT for coronary arterybypass grafting (CABG) and removal of IVC/intra-cardiac tumor thrombus. However, as her SRA and EIA remained strongly positive (99% serotonin-release at 0.3 IU/mL UFH; IgG- 
Methods
Testing for HIT antibodies was performed using the SRA and an in-house anti-PF4/heparin IgGspecific EIA (McMaster Platelet Immunology Laboratory), as described. 5, 6 Serial serum samples were drawn for HIT antibody testing immediately pre-and post-each TPE session. SRA-positive control sera obtained from 15 different patients previously diagnosed with HIT (each serum yielding >50% serotonin-release at 0.3 U/mL UFH) were tested in four-fold serial dilutions (1/5 to 1/5120). The SRAs were performed over two days, and the EIA-IgG in one day using 3 plates, with internal HIT-positive and -negative control sera producing expected results. For comparison, sera are usually diluted 1/5 (final) in our SRA and 1/50 (final) in our EIA-IgG. Further, when we compared the corresponding EIAs for the most dilute (but still SRA-positive) sera versus the corresponding four-fold more dilute (but now SRA-negative) sera, the mean OD values were similar (2.75 vs 2.60, respectively; P = .157) (Fig. 2B) . Interestingly, the maximum OD reactivity (at any dilution) was similar to the OD reactivity of the most diluted, but still SRA-positive sample.
Results and Discussion
For HIT diagnosis) even when their sera had become negative by washed platelet activation assay. 9, 10 In summary, our observations indicate that diluted HIT serum-whether achieved clinically through serial TPE, or experimentally through serial sample dilutions-demonstrates loss of SRA reactivity well before a decrease in EIA reactivity. These findings point to the importance of performing platelet activation assays in parallel with the EIA, when testing preand post-TPE samples, when judging patient suitability for a planned heparin re-exposure. 
